Page 1

geron 11/9/2021 Geron Presents Investor Event Highlights Strong Evidence of Disease - Modifying Activity of Imetelstat Provides Compelling Differentiation for Phase 3 Development Programs in Lower Risk MDS and Refractory MF Significant Unmet Needs in Lower Risk MDS and Refractory MF Addressable by Imetelstat Provide Potential Large Market Opportunities New Programs Expand Potential Indications and Combination Opportunities for Imetelstat Third Quarter and Year to Date 2021 Financial Results Also Reported FOSTER CITY , Calif .-- ( BUSINESS WIRE ) -- Geron Corporation ( Nasdaq : GERN ) , a late - stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies , summarized key highlights from its Investor Event held on November 9. An archive of the presentation webcast is available through the Investor Relations section of Geron's website under Events . The Company also reported its financial results for the third quarter and year to date 2021 periods . As of September 30 , 2021 , the Company had $ 215.8 million in cash and marketable securities . These financial resources , combined with expected future non - dilutive funding under a current debt facility , are expected to be sufficient to fund current operations , including the new programs presented at the Investor Event , through the end of the first quarter of 2023 . " By targeting telomerase , imetelstat inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies , resulting in malignant cell apoptosis and potential disease - modifying activity , " said John A. Scarlett , M.D. , Chairman and Chief Executive Officer . " The compelling efficacy , molecular and cytogenetic data from our Phase 2 trials in lower risk MDS and myelofibrosis patients indicate the potential modification of those underlying diseases , which gives us further confidence in the transformational potential of imetelstat and that the Phase 2 results will be confirmed in our ongoing Phase 3 trials . Our vision aims to bring this same disease modification potential to patients across multiple hematologic malignancies . " Investor Event Highlights 1